StockData
NovaBridge Biosciences logo

NovaBridge Biosciences (NBP) company profile

NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 0/30
$0.82+0.03 (+3.89%)

Close on Nov 17, 2026Market cap $94.88MP/E –Yield –

About NovaBridge Biosciences

Pharmaceutical Preparations, SIC 2834

NovaBridge Biosciences is a clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel or differentiated biologic therapeutics. The company primarily directs its research efforts toward treatments in the fields of oncology and ophthalmology. It advances a proprietary pipeline of investigational drug candidates alongside partnered development programs with international pharmaceutical organizations. Its customer and collaborator base comprises global biopharmaceutical licensees, commercial healthcare providers, and targeted patient populations requiring advanced biologic interventions.

Incorporated as an exempted company in the Cayman Islands, the organization maintains its principal executive offices in Rockville, Maryland, United States. Its continuing business operations and clinical pipeline activities are managed through operating subsidiaries located in the United States and China following the divestiture of its former Greater China business unit.

Summary of the business section of NovaBridge Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
NovaBridge Biosciences
Headquarters
Rockville, MD
Address
Suite 400, 2440 Research Blvd 20850
Phone
(301) 670-2800
Employees
220, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers Zhong Tian LLP, Shanghai, the Peoples Republic of China

Stock & identifiers

Ticker
NBP
Former tickers
IMAB until Apr 7, 2026
Exchange
Nasdaq
IPO date
Jan 21, 2020
Shares outstanding
265M, Dec 31, 2025
Filer category
Non-accelerated filer
SEC CIK
1778016
CUSIP
44975P103
ISIN
US44975P1030
FIGI
BBG00QQ8DFK6
Share class FIGI
BBG00QQ8DG97
LEI
549300L1A5T19703RR64
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Srishti GuptaChief Executive Officer, Director–
Xi-Yong FuSee Remarks, Director59,823
Charles SilbersteinChief Financial Officer–
Phillip Andrew DennisChief Medical Officer173,427
Sean Wuxiong CaoChief Bus. Development Officer266,467
Cong Claire XuEVP, Clinical Development304,201
Mark Arnold HaglerChief Commercial Officer230,000
Liwei Lorraine LinGeneral Counsel–
Denny Hsueh Wen ChuSee Remarks–
Xiaofan Neo ZhangChief Investment Officer874,000
Ming Kyler LeiChief Financial Officer–
Adeline Yi ZhangGlobal Controller–
Joanna Xuqiong WuSee Remarks5,750
Ian Ying WooDirector13,271
Martin William DewhurstDirector–
Robert A. LenzDirector17,218
Wei FuDirector30,499,699
Conor Chia-hung YangDirector–
Chun Kwok Alan AuDirector–
Xin LiuDirector–
Emmett CunninghamDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 21, 2020
Securities offered
7,407,400
Exchange
Nasdaq
First trading day
Jan 21, 2020
First-day close
$13.80
Lock-up ends (est.)
Jul 19, 2020

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had 30, 32, and 220 employees as of December 31, 2025, 2024 and 2023, respectively.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 28, 2025Name changeName changed from I-Mab to NovaBridge Biosciences
Jan 21, 2020IPOInitial public offering priced (424B4 prospectus)
Jan 3, 2020ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?